1.
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer.
Nat Rev Dis Primers 2019;5:66
2.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med
2010;363:1938-48
3.
Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution
spectrum of primary triple-negative breast cancers. Nature 2012;486:395-9
4.
Caparica R, Lambertini M, de Azambuja E. How I treat metastatic triple-negative breast cancer.
ESMO Open 2019;4:e000504
5.
Cyprian FS, Akhtar S, Gatalica Z, Vranic S. Targeted immunotherapy with a checkpoint inhibitor
in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative
breast cancer. Bosn J Basic Med Sci 2019;19:227-33
6.
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1
expression in triple-negative breast cancer. Cancer Immunol Res 2014;2:361-70
7.
Agrawal S, Kandimalla ER. Intratumoural immunotherapy: activation of nucleic acid sensing
pattern recognition receptors. Immuno-Oncology Technology 2019;3:15-23
8.
Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity
in cancer therapy. Nature 2019;574:45-56
9.
Elion DL, Jacobson ME, Hicks DJ, Rahman B, Sanchez V, Gonzales-Ericsson PI, et al.
Therapeutically active RIG-I agonist induces immunogenic tumor cell killing in breast cancers.
Cancer Res 2018;78:6183-95
10.
Loo YM, Gale M, Jr. Immune signaling by RIG-I-like receptors. Immunity 2011;34:680-92
11.
Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-20
12.
Elion DL, Cook RS. Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for
therapeutic cancer treatment. Oncotarget 2018;9:29007-17
13.
Aznar MA, Planelles L, Perez-Olivares M, Molina C, Garasa S, Etxeberria I, et al.
Immunotherapeutic effects of intratumoral nanoplexed poly I:C. J Immunother Cancer 2019;7:116
14.
Márquez-Rodas I, Longo F, Rodriguez-Ruiz ME, Calles A, Ponce S, Jove M, et al. Intratumoral
nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1refractory tumors. Sci Transl Med 2020;12
15.
Miyazono K, Katsuno Y, Koinuma D, Ehata S, Morikawa M. Intracellular and extracellular TGFβ signaling in cancer: some recent topics. Front Med 2018;12:387-411
16.
Derynck R, Budi EH. Specificity, versatility, and control of TGF-β family signaling. Sci Signal
2019;12
76
17.
Ikushima H, Miyazono K. TGFβ signalling: a complex web in cancer progression. Nat Rev Cancer
2010;10:415-24
18.
Massague J. TGFβ in cancer. Cell 2008;134:215-30
19.
Arase M, Tamura Y, Kawasaki N, Isogaya K, Nakaki R, Mizutani A, et al. Dynamics of chromatin
accessibility during TGF-β-induced EMT of Ras-transformed mammary gland epithelial cells. Sci
Rep 2017;7:1166
20.
Katsuno Y, Meyer DS, Zhang Z, Shokat KM, Akhurst RJ, Miyazono K, et al. Chronic TGF-β
exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to
bitopic mTOR inhibition. Sci Signal 2019;12
21.
Sundqvist A, Morikawa M, Ren J, Vasilaki E, Kawasaki N, Kobayashi M, et al. JUNB governs a
feed-forward network of TGFβ signaling that aggravates breast cancer invasion. Nucleic Acids
Res 2018;46:1180-95
22.
Vasilaki E, Morikawa M, Koinuma D, Mizutani A, Hirano Y, Ehata S, et al. Ras and TGF-β
signaling enhance cancer progression by promoting the ΔNp63 transcriptional program. Sci Signal
2016;9:ra84
23.
Ehata S, Hanyu A, Hayashi M, Aburatani H, Kato Y, Fujime M, et al. Transforming growth factorβ promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription
factor DEC1. Cancer Res 2007;67:9694-703
24.
Fang Y, Chen Y, Yu L, Zheng C, Qi Y, Li Z, et al. Inhibition of breast cancer metastases by a novel
inhibitor of TGFβ receptor 1. J Natl Cancer Inst 2013;105:47-58
25.
Chen XH, Liu ZC, Zhang G, Wei W, Wang XX, Wang H, et al. TGF-β and EGF induced HLA-I
downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation
of snail in prostate cancer cells. Mol Immunol 2015;65:34-42
26.
Xu P, Bailey-Bucktrout S, Xi Y, Xu D, Du D, Zhang Q, et al. Innate antiviral host defense
attenuates TGF-β function through IRF3-mediated suppression of Smad signaling. Mol Cell
2014;56:723-37
27.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of
human triple-negative breast cancer subtypes and preclinical models for selection of targeted
therapies. J Clin Invest 2011;121:2750-67
28.
Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and
collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 2013;14:128
29.
Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a
comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res
2016;44:W90-7
30.
Harada M, Morikawa M, Ozawa T, Kobayashi M, Tamura Y, Takahashi K, et al. Palbociclib
enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer. Cancer Sci
77
2019;110:209-20
31.
Golden RJ, Chen B, Li T, Braun J, Manjunath H, Chen X, et al. An Argonaute phosphorylation
cycle promotes microRNA-mediated silencing. Nature 2017;542:197-202
32.
Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ, et al. The androgen
receptor represses transforming growth factor-β signaling through interaction with Smad3. J Biol
Chem 2002;277:1240-8
33.
Yang KM, Kim W, Bae E, Gim J, Weist BM, Jung Y, et al. DRAK2 participates in a negative
feedback loop to control TGF-β/Smads signaling by binding to type I TGF-β receptor. Cell Rep
2012;2:1286-99
34.
Mori M, Yoneyama M, Ito T, Takahashi K, Inagaki F, Fujita T. Identification of Ser-386 of
interferon regulatory factor 3 as critical target for inducible phosphorylation that determines
activation. J Biol Chem 2004;279:9698-702
35.
Higgs R, J NG, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52
negatively regulates IFN-β production post-pathogen recognition by polyubiquitin-mediated
degradation of IRF3. J Immunol 2008;181:1780-6
36.
Lei CQ, Zhang Y, Xia T, Jiang LQ, Zhong B, Shu HB. FoxO1 negatively regulates cellular antiviral
response by promoting degradation of IRF3. J Biol Chem 2013;288:12596-604
37.
Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, et al. LRRC15 is a novel
mesenchymal protein and stromal target for antibody-drug conjugates. Cancer Res 2018;78:405972
38.
Broz P, Pelegrín P, Shao F. The gasdermins, a protein family executing cell death and inflammation.
Nat Rev Immunol 2020;20:143-57
39.
Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through
caspase-3 cleavage of a gasdermin. Nature 2017;547:99-103
40.
Smith SE, Mellor P, Ward AK, Kendall S, McDonald M, Vizeacoumar FS, et al. Molecular
characterization of breast cancer cell lines through multiple omic approaches. Breast Cancer Res
2017;19:65
41.
Thompson DA, Weigel RJ. Characterization of a gene that is inversely correlated with estrogen
receptor expression (ICERE-1) in breast carcinomas. Eur J Biochem 1998;252:169-77
42.
David CJ, Massagué J. Contextual determinants of TGFβ action in development, immunity and
cancer. Nat Rev Mol Cell Biol 2018;19:419-35
43.
Kim IS, Gao Y, Welte T, Wang H, Liu J, Janghorban M, et al. Immuno-subtyping of breast cancer
reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nat Cell Biol
2019;21:1113-26
44.
Jorgensen I, Rayamajhi M, Miao EA. Programmed cell death as a defence against infection. Nat
Rev Immunol 2017;17:151-64
78
45.
Yu X, Wang H, Li X, Guo C, Yuan F, Fisher PB, et al. Activation of the MDA-5-IPS-1 viral sensing
pathway induces cancer cell death and type I IFN-dependent antitumor immunity. Cancer Res
2016;76:2166-76
46.
Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, et al. Tumor
innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med
2018;24:1143-50
47.
Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, et al. LSD1 ablation
stimulates anti-tumor immunity and enables checkpoint blockade. Cell 2018;174:549-63.e19
48.
Besch R, Poeck H, Hohenauer T, Senft D, Häcker G, Berking C, et al. Proapoptotic signaling
induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human
melanoma cells. J Clin Invest 2009;119:2399-411
49.
Bhoopathi P, Quinn BA, Gui Q, Shen XN, Grossman SR, Das SK, et al. Pancreatic cancer-specific
cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid. Cancer Res
2014;74:6224-35
50.
Tormo D, Checińska A, Alonso-Curbelo D, Pérez-Guijarro E, Cañón E, Riveiro-Falkenbach E, et
al. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in
melanoma cells. Cancer Cell 2009;16:103-14
51.
Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, et al. PARP
inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway
activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov 2019;9:72237
52.
Reisländer T, Groelly FJ, Tarsounas M. DNA damage and cancer immunotherapy: A STING in the
tale. Mol Cell 2020;80:21-8
53.
Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, et al.
Neoadjuvant interferons: critical for effective PD-1-based immunotherapy in TNBC. Cancer
Immunol Res 2017;5:871-84
54.
Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer
Discov 2020;10:26-39
55.
Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, et al. Targeting DNA damage
response promotes antitumor immunity through STING-mediated T-cell activation in small cell
lung cancer. Cancer Discov 2019;9:646-61
56.
Lönn P, van der Heide LP, Dahl M, Hellman U, Heldin CH, Moustakas A. PARP-1 attenuates
Smad-mediated transcription. Mol Cell 2010;40:521-32
57.
Honda K, Takaoka A, Taniguchi T. Type I interferon gene induction by the interferon regulatory
factor family of transcription factors. Immunity 2006;25:349-60
58.
Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol 2012;13:616-30
79
59.
Qin BY, Liu C, Lam SS, Srinath H, Delston R, Correia JJ, et al. Crystal structure of IRF-3 reveals
mechanism of autoinhibition and virus-induced phosphoactivation. Nat Struct Biol 2003;10:91321
60.
Takahasi K, Suzuki NN, Horiuchi M, Mori M, Suhara W, Okabe Y, et al. X-ray crystal structure
of IRF-3 and its functional implications. Nat Struct Biol 2003;10:922-7
61.
Chipuk JE, Bhat M, Hsing AY, Ma J, Danielpour D. Bcl-xL blocks transforming growth factor-β
1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1dependent caspase activation in prostate epithelial cells. J Biol Chem 2001;276:26614-21
62.
Francis JM, Heyworth CM, Spooncer E, Pierce A, Dexter TM, Whetton AD. Transforming growth
factor-β 1 induces apoptosis independently of p53 and selectively reduces expression of Bcl-2 in
multipotent hematopoietic cells. J Biol Chem 2000;275:39137-45
63.
Lafon C, Mathieu C, Guerrin M, Pierre O, Vidal S, Valette A. Transforming growth factor β 1induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant Nacetylcysteine and bcl-2. Cell Growth Differ 1996;7:1095-104
64.
Franco DL, Mainez J, Vega S, Sancho P, Murillo MM, de Frutos CA, et al. Snail1 suppresses TGFβ-induced apoptosis and is sufficient to trigger EMT in hepatocytes. J Cell Sci 2010;123:3467-77
65.
Prehn JH, Bindokas VP, Marcuccilli CJ, Krajewski S, Reed JC, Miller RJ. Regulation of neuronal
Bcl2 protein expression and calcium homeostasis by transforming growth factor type β confers
wide-ranging protection on rat hippocampal neurons. Proc Natl Acad Sci U S A 1994;91:12599603
66.
Saile B, Matthes N, El Armouche H, Neubauer K, Ramadori G. The bcl, NFκB and p53/p21WAF1
systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-β or TNFα on activated hepatic stellate cells. Eur J Cell Biol 2001;80:554-61
67.
Maedler K, Fontana A, Ris F, Sergeev P, Toso C, Oberholzer J, et al. FLIP switches Fas-mediated
glucose signaling in human pancreatic β cells from apoptosis to cell replication. Proc Natl Acad
Sci U S A 2002;99:8236-41
68.
Plaza-Sirvent C, Schuster M, Neumann Y, Heise U, Pils MC, Schulze-Osthoff K, et al. c-FLIP
expression in Foxp3-expressing cells is essential for survival of regulatory T cells and prevention
of autoimmunity. Cell Rep 2017;18:12-22
69.
Schlapbach R, Spanaus KS, Malipiero U, Lens S, Tasinato A, Tschopp J, et al. TGF-β induces the
expression of the FLICE-inhibitory protein and inhibits Fas-mediated apoptosis of microglia. Eur
J Immunol 2000;30:3680-8
70.
Kang JS, Alliston T, Delston R, Derynck R. Repression of Runx2 function by TGF-β through
recruitment of class II histone deacetylases by Smad3. Embo j 2005;24:2543-55
71.
Guikema JE, Amiot M, Eldering E. Exploiting the pro-apoptotic function of NOXA as a
therapeutic modality in cancer. Expert Opin Ther Targets 2017;21:767-79
80
72.
Kang Y, Chen CR, Massagué J. A self-enabling TGFβ response coupled to stress signaling: Smad
engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 2003;11:91526
73.
Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol
2001;113-4.
74.
Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, et al. Caspase-11 cleaves
gasdermin D for non-canonical inflammasome signalling. Nature 2015;526:666-71
75.
Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory
caspases determines pyroptotic cell death. Nature 2015;526:660-5
76.
Zhou Z, He H, Wang K, Shi X, Wang Y, Su Y, et al. Granzyme A from cytotoxic lymphocytes
cleaves GSDMB to trigger pyroptosis in target cells. Science 2020;368
77.
Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, et al. Mutant BRAF and MEK
inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov
2020;10:254-69
78.
Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by
activating anti-tumour immunity. Nature 2020;579:415-20
79.
Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination
immunotherapies. Nat Rev Drug Discov 2019;18:197-218
81
謝辞
本研究を遂行するにあたり、多大なるご指導ご鞭撻を頂きました東京大学医学系研究科
分子病理学教室の宮園浩平教授に深く感謝申し上げます。また、手技的なものから研究
方針へのアドバイスまで、長きにわたりアドバイスを賜りました鯉沼代造准教授に感謝
申し上げます。また、実験の進行に関するご助言を賜りました森川真大助教、田邊諒博
士に感謝申し上げます。更に、技術的にご支援くださった森下保幸さん、結城圭子さん
にも感謝申し上げます。また、全般にわたり、ご助言いただきました江幡正悟准教授、
勝野蓉子助教、髙橋恵生助教をはじめとする東京大学医学系研究科分子病理学教室の皆
様にも感謝申し上げます。また、研究の遂行を支援してくださった一條秀憲教授に深く
感謝申し上げます。更に、本研究を遂行するにあたり、ベクターを供与してくださった
元慶應大学の故 三好浩之先生、Massachusetts Institute of Technology の Feng Zhang 先生
に感謝申し上げます。また、GO 解析にてそのプラットホームを提供して下さったウェ
ブツール Enrichr に関わった方々にも感謝申し上げます (28,29)。
82
...
論文の公開元へ
